Geode Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-494,234
Closed -$4.64M 4335
2020
Q3
$4.64M Sell
494,234
-5,682
-1% -$54K ﹤0.01% 2434
2020
Q2
$3.82M Sell
499,916
-571
-0.1% -$4.37K ﹤0.01% 2493
2020
Q1
$3.09M Buy
500,487
+25,861
+5% +$228K ﹤0.01% 2427
2019
Q4
$5.78M Buy
474,626
+16,607
+4% +$181K ﹤0.01% 2362
2019
Q3
$5.29M Buy
458,019
+1,353
+0.3% +$14.2K ﹤0.01% 2352
2019
Q2
$4.56M Sell
456,666
-18,421
-4% -$199K ﹤0.01% 2458
2019
Q1
$6.12M Buy
475,087
+40,282
+9% +$600K ﹤0.01% 2215
2018
Q4
$6.6M Sell
434,805
-683
-0.2% -$13K ﹤0.01% 2052
2018
Q3
$8.71M Buy
435,488
+31,038
+8% +$707K ﹤0.01% 2029
2018
Q2
$7.88M Buy
404,450
+34,894
+9% +$772K ﹤0.01% 2056
2018
Q1
$7.45M Sell
369,556
-7,923
-2% -$134K ﹤0.01% 1981
2017
Q4
$5M Buy
377,479
+5,452
+1% +$82.2K ﹤0.01% 2215
2017
Q3
$6.86M Buy
372,027
+8,709
+2% +$162K ﹤0.01% 2005
2017
Q2
$6.68M Buy
363,318
+830
+0.2% +$16.4K ﹤0.01% 1948
2017
Q1
$8.17M Buy
362,488
+56,493
+18% +$1.35M ﹤0.01% 1758
2016
Q4
$10.6M Buy
305,995
+15,010
+5% +$448K 0.01% 1523
2016
Q3
$7.13M Buy
290,985
+7,336
+3% +$183K ﹤0.01% 1718
2016
Q2
$6.78M Buy
283,649
+20,801
+8% +$477K ﹤0.01% 1697
2016
Q1
$6.15K Buy
262,848
+10,067
+4% +$239K ﹤0.01% 1738
2015
Q4
$7.63M Buy
252,781
+17,850
+8% +$577K ﹤0.01% 1570
2015
Q3
$9.33M Buy
234,931
+36,722
+19% +$2.28M 0.01% 1391
2015
Q2
$13.7M Buy
198,209
+25,241
+15% +$1.59M 0.01% 1198
2015
Q1
$9.45M Buy
172,968
+43,113
+33% +$2.05M 0.01% 1432
2014
Q4
$5.53M Buy
129,855
+3,133
+2% +$113K ﹤0.01% 1750
2014
Q3
$4.04M Buy
126,722
+2,213
+2% +$47.2K ﹤0.01% 1897
2014
Q2
$2.58M Buy
124,509
+4,165
+3% +$77K ﹤0.01% 2218
2014
Q1
$2.33M Buy
120,344
+3,230
+3% +$68.6K ﹤0.01% 2247
2013
Q4
$2.84M Buy
117,114
+7,825
+7% +$184K ﹤0.01% 2090
2013
Q3
$2.35M Buy
109,289
+2,971
+3% +$70.2K ﹤0.01% 2074
2013
Q2
$2.37M Buy
+106,318
New +$2.34M ﹤0.01% 1942

Geode Capital Management's AMAG Position: Q4 2020 in Review

Geode Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 494,234 shares — an estimated $4.64M sold.

Geode Capital Management first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $13.7M in Q2 2015. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.

  • Geode Capital Management reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Geode Capital Management sold 494,234 AMAG Pharmaceuticals shares in Q4 2020, an estimated $4.64M.
  • Geode Capital Management first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
  • Geode Capital Management's AMAG Pharmaceuticals position peaked at $13.7M in Q2 2015.
  • 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.

Based on Geode Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.